EURASIAN JOURNAL OF ACADEMIC RESEARCH
Innovative Academy Research Support Center
IF = 9.3 www.in-academy.uz/index.php/ejar

THE IMPORTANCE OF DRUGS ACTING ON ADRENORECEPTORS IN MEDICAL PRACTICE AND THE RELEVANCE OF IMPROVING THEIR USE

Sokhib Rashidov Zamon o'g'li
Khilola Musaeva Usmonqul qizi
Shokhidakhon Burkhonidinova Dilshodbek qizi
Department of Pharmacology of Tashkent State Medical University.
e-mail: rashidovsohib9295@gmail.com
https://doi.org/10.5281/zenodo.17357514

ARTICLE INFO

Received: 05st October 2025
Accepted: 10th October 2025
Online: 15th October 2025

KEYWORDS

Alzheimer's disease, tauopathies, beta amyloid, neurodegeneration, neuroinflammation, adrenergic receptors, adrenergic agonists, adrenergic antagonists.

ABSTRACT

Since there are currently no effective disease-modifying medications available, neurodegenerative diseases—of which Alzheimer's disease (AD) is the most common—are among the most debilitating illnesses. The hallmarks of AD, a complex multifactorial neurodegenerative disease, are memory loss and gradual, severe cognitive impairment. It is the most frequent cause of progressive memory loss (dementia) in the elderly, and there is currently no cure or significant slowing of the disease's progression. It is not well known or studied how adrenergic receptors contribute to the pathophysiology of tauopathies, including Alzheimer's disease. Recent research has suggested that medications that target adrenergic receptors may help treat AD and dementias, although overall findings are still unclear because of the variety of pharmacological classes being tried. This review article's goal is to thoroughly examine the literature on the potential involvement of adrenergic receptors in neurodegenerative diseases. This includes studies on these receptors in animal models and in vitro, as well as the use of agonists and antagonists, such as antihypertensive and asthma medications, that act on the receptors. Given their lengthy history of usage and safety, we ultimately intend to better understand the function of these receptors, pinpoint knowledge gaps, and investigate the potential for repurposing such medications for AD. A major obstacle in the development of selective modulators is the dual nature of receptor activity, where both activation and blockage may have comparable effects. Further

complicating studies in this field and therapeutic methods are genetic factors, patient-specific characteristics, the disease's intricacy, and the dearth of reliable animal models. Subtype-specific medication development, combination therapy, and more controlled clinical trials with suitable covariate selection should be the main priorities of future research. Big data and sophisticated analytical approaches could also be used to improve adrenergic modulation strategies in AD. In addition to AD, this may result in novel therapies for other neurodegenerative illnesses as well.

Introduction. Alzheimer's disease (AD) is the most prevalent and common form of dementia, posing a serious threat to global health and having disastrous effects on patients, caregivers, and healthcare systems. It is a degenerative disease that eventually causes memory loss, cognitive impairment, and the inability to carry out even basic everyday duties. There are millions of people with AD, and as the population ages, that number is predicted to rise significantly. There are currently no disease-modifying therapies that potentially change the course of AD, despite extensive research on the condition. The majority of current treatment methods are symptomatic in nature and only slightly and temporarily improve cognitive function without changing the causes underlying neurodegeneration. Multiple pathogenic characteristics, including amyloid-beta (Aβ) accumulation, tau protein hyperphosphorylation, neuroinflammation, loss of synaptic connection, and cardio-vascular abnormalities, are linked to AD, a complicated condition. These mechanisms are interconnected and ultimately lead to neuronal degeneration [1-5]. The noradrenergic system, and more especially adrenergic receptors (ARs), has recently come into the spotlight as a major contributing element to the development of Alzheimer's disease. GPCRs known as adrenergic receptors are primarily responsible for reacting to norepinephrine (NE) or epinephrine in the brain, which regulates cognitive, vascular, and inflammatory processes. The early degradation of the locus coeruleus (LC), one of the few areas that produces NE and is impacted in AD, results in this dysregulation, which is followed by the loss of the non-adrenergic system and innervation. The two types of adrenergic receptors, α and β, each have distinct signaling pathways and functions. The majority of the Central Nervous System (CNS) contains these receptors, which play a crucial role in the regulation of neuroinflammation, neurovascular coupling, synaptic plasticity, and other metabolic processes. In AD, LC degeneration also results in a significant hypofunction of NE transmission, which has neurological implications that are expected to increase the toxicity of Aβ, encourage tau buildup, and harm neurons. A wide class of pharmaceuticals known as "adrenergic drugs" attaches itself to adrenergic receptors all over the body [6-12]. Alpha-1, alpha-2, beta-1, beta-2, and beta-3 are some of these receptors. To produce a variety of physiological effects, adrenergic medications will directly bind to one or more of these receptors. It is necessary to categorize adrenergic medications according to the particular receptors they

bind. The pharmacology, different therapeutic benefits, and adverse events that class members may experience—which encompass a broad range of clinical manifestations—are all examined in this activity. Cell-surface receptors called beta-2 adrenergic receptors are used clinically to treat bronchospasm in individuals with bronchial asthma and chronic obstructive pulmonary disease. Both agonistic and antagonistic drugs target these receptors. There are no specific beta-2 antagonists; instead, agonistic medications that stimulate the receptors are either nonselective, which stimulates all beta subtypes, including beta-2, or selective to the beta-2 subtype. The mechanism of action of beta-2 receptors, indications, administration routes, bad effects, monitoring, contraindications, and certain guidelines for the use of drugs that target the receptors, primarily in patients with bronchospastic disorders, will all be covered in this activity. Adrenergic receptors are thought to be interesting candidates for AD medication development because of their widespread expression and variety of functions [13-17]. Many medications that target adrenergic receptors are currently being utilized in clinical practice to treat a variety of conditions, including bronchial asthma, hypertension, and some mental illnesses. This is beneficial since it enables the repurposing of these medications for the treatment of AD without the need for lengthy clinical trials. The question of whether they can be helpful is still up for debate, though, as they appear to be helpful occasionally but not always. Therefore, depending on the receptor subtypes, brain areas, and stage of the disease, possible regulation of these receptors should be executed in a very precise way. It's unclear, nevertheless, if blocking or activating adrenergic receptors is advantageous. Using knowledge from preclinical models, genetic research, and clinical trials, this review assesses the data on the function of adrenergic receptors in AD in a unified and thorough way [18-21].

The main purpose of the presented analytical manuscript is to provide a brief overview based on reputable scientific studies on the importance of drugs acting on adrenoreceptors in medical practice and the relevance of improving their use.

The receptors for α-adrenergic. The complex roles that α-ARs play in neurodegeneration, especially in AD and associated tauopathies, make them unique among the adrenergic receptor subtypes. These G-protein-coupled receptors are divided into two categories: α1 and α2 adrenergic receptors. They are crucial for inflammation, neurovascular activity, and synaptic plasticity and are normally triggered by norepinephrine (NE). They are at the core of the neurodegeneration linked to Alzheimer's disease pathology because of their extensive innervation and moderating effect on tau pathology and Aβ processing. The dual nature of α-ARs complicates their therapeutic efficacy. Preclinical research has demonstrated that α1-ARs are neuroprotective and have the strongest effect; activation of these receptors has been linked to improved synaptic function, decreased neuroinflammation, and improved cognitive outcomes. Similarly, selective α2-AR agonists increase neurogenic processes while decreasing amyloidogenic processes, both of which are highly beneficial in treatment [11,12,14]. However, there are certain problems with such receptors. Some AD patients have agonistic α1-AR autoantibodies in their blood, which overstimulate those receptors over time, causing neurotoxic and vasculotoxic consequences. However, the encouragement of amyloid

formation and pathological activation of amyloid precursor protein (APP) upon receptor stimulation are possible side effects of α2-ARs. Understanding of α-ARs' functions in the pathophysiology of AD has significantly improved in recent years due to research on their genetic, molecular, and pharmacological features. The positive and negative effects of α-ARs in AD are examined in this section, along with how they may mediate dementia control [4,5,7].

The ability of α1 adrenergic receptors (α1-ARs) to impact important systems underlying brain function and pathology has made them a focus of attention in the setting of AD and other neurodegenerative disorders. Studies showing the protective effects of activating these receptors as well as the advantages of selective inhibition highlight their medicinal potential. The intricacy of α1-AR signaling and its part in neurodegeneration are highlighted by these seemingly incongruous results. In this field, the identification of positive allosteric modulators (PAMs) for α1A-ARs is a promising breakthrough. In AD animal models, it has been demonstrated that Compound 3 (Cmpd-3), a PAM for α1A-ARs, may restore LTP deficits and restore normal levels of amyloid β (Aβ)-40 and -42. Blood pressure, a typical issue with adrenergic receptor-targeted treatments, was not affected by these effects [7,8,9]. Moreover, donepezil, the conventional acetylcholinesterase inhibitor treatment for AD, was not as effective in improving cognitive function as Cmpd-3, which was administered orally once daily for three months at doses ranging from 3 to 9 mg/kg. These results demonstrate PAM's potential as a disease-modifying drug with strong therapeutic efficacy, similar to that of Cmpd-3. Additionally, compared to α1AAR knockout mice, mice with constitutively active α1AAR shown improvements in memory and learning. Cirazoline, an α1AAR-selective agonist, similarly improved cognitive capabilities in WT mice, indicating that sustained α1AAR stimulation enhances synaptic plasticity, cognitive function, mood, and longevity. These results highlight the neuroprotective and anti-inflammatory properties of α1-AR antagonists in AD. Terazosin, another α1-AR antagonist, has shown a new way to reduce neurodegenerative disease. Terazosin decreased pathogenic protein aggregation in AD and other neurodegenerative disease models by raising ATP levels and promoting autophagy, indicating its potential as a therapeutic approach. Terazosin has also been demonstrated to lessen glial activation, tau hyperphosphorylation, and the load of amyloid plaque. Terazosin therapy also markedly corrected behavioral impairments in AD animals. These results imply that selective inhibition of α1-ARs may provide a possible therapeutic avenue by counteracting the degenerative mechanisms underlying AD [13,14,15].

The α2-Adrenergic Glands. Since both activation and blockade have been demonstrated to be neuroprotective, with the majority of studies favoring blockade over activation for protection, the α2 adrenergic receptors (α2-ARs) have also been linked to neuroprotection and cognitive enhancement in AD and other neurodegenerative disorders with varying degrees of success. Additional proof of α2-ARs' protective function has come from genetic research. In 311 Greek subjects, a deletion variant of the α2b-adrenergic receptor has been linked to improved memory development and a lower risk of developing AD. This variation may be a protective genetic factor because it was more common in control subjects than in people with AD or mild cognitive impairment.

There has been promise in pharmacologically modulating α2C-ARs (α2 subtype C). A specific α2C-AR antagonist, ORM-10921, reduced symptoms of CNS diseases, including AD, and enhanced cognitive performance as assessed by water maze [7,8,9]. Its potential as a tailored treatment for neurological illnesses is supported by its strong selectivity for the α2C-AR subtype. Together with these pharmaceutical discoveries, dexefaroxan, an α2-adrenoceptor antagonist, has been shown to improve neuron survival, providing a fresh strategy for maintaining cognitive function in neurodegenerative diseases. Dexefaroxan's therapeutic promise was further supported by the fact that it enhanced memory function and decreased cholinergic degeneration in animal models. Mesedin, another α2-adrenoblocker, has shown several neuroprotective properties in vivo, such as lowering neuroinflammation, boosting Aβ breakdown, raising choline acetyltransferase levels, and having anti-amyloidogenic action. These results demonstrate the complex function of α2-AR regulation in reducing AD pathogenesis [12,13,14]. However, noradrenergic dysregulation has been linked to the progression of AD, and the α2A adrenergic receptor has also been implicated in the acceleration of Aβ production. Sorting-related receptors with A repeat (SorLA), a crucial regulator of APP trafficking, and APP interact when α2A-ARs are activated. This disruption makes it easier for APP to be redistributed to endosomes, where β-secretase cleaves it, increasing the formation of Aβ. In an AD transgenic paradigm, Idazoxan-induced α2AR blockade improved cognitive impairments and decreased AD-related pathologies. Brimonidine and clonidine are examples of agonists that have shown significant neuroprotective effects, especially by lowering the death of retinal ganglion cells. This is accomplished via decreasing Aβ and APP processing, highlighting the therapeutic value of α2-ARs in diseases with amyloid pathology [1,2,7,8,9].

The receptors for β-adrenergic. A unique and important member of the adrenergic receptor family, β-ARs play important roles in the pathogenesis of AD. The main function of β-ARs is to control intracellular signaling pathways that affect energy metabolism, synaptic plasticity, and neuroinflammation. These G-protein-coupled receptors, which are widely dispersed throughout the brain and activated by NE and epinephrine, are divided into three subtypes: β1, β2, and β3. They are important modulators of cellular processes that are directly linked to AD pathogenesis because of their interactions with cAMP-mediated pathways. The various functions of β-ARs in AD are discussed in this section, along with how they affect the course of the illness and possible treatments [9-12]. β-Adrenergic Receptors' Beneficial Functions in Alzheimer's Disease and Other Neurodegenerative Conditions. Adrenergic receptors of β1. Because the β1-ARs modulate cognitive skills like memory and social learning, they have become a prospective therapeutic target in AD and other neurodegenerative illnesses. Crucially, every study shows that β1 receptor activation mediates the protective effects. The medial amygdala is a crucial region of β1-AR activity, where these receptors aid in social cue processing and learning. Preclinical research has successfully addressed social recognition dysfunction by selectively activating β1-ARs. Through the activation of the protein kinase A (PKA)/phosphorylated cAMP-response element-binding protein (phospho-CREB) signaling cascade, Xamoterol, a selective partial β1-AR agonist, was demonstrated to

restore social recognition impairments in an AD mouse model (APP). These receptors are important targets for AD as well as other neurodegenerative and neuroinflammatory diseases since β1-AR-targeted treatments can alter neuroinflammatory pathways. The impact of β1-AR regulation on intracellular signaling cascades is intimately linked to its neuroprotective properties. When β1-ARs are activated, more cAMP is produced, which in turn stimulates PKA and other downstream signaling molecules like CREB. The transcription of neuroprotective genes, such as those pertaining to synaptic repair and neuronal survival, is encouraged by this cascade. Moreover, β1-ARs seem to control neuroinflammation by blocking pro-inflammatory cytokines such as TNF-α, offering a two-pronged method of action that targets the immunological and neuronal aspects of neurodegeneration [12-16].

The toxicity and Contraindications. Drug antagonists exist for all adrenergic receptors. Alpha-blockers are often not recommended for the treatment of excessive alpha-agonist use. Adrenergic receptor agonist side effects can be rapidly treated with beta-blockers. Vasopressor-induced hypertension and tachycardia can be treated with beta-blockers. Because beta-2 agonists can raise liver aminotransferase levels, their toxicity should be closely watched in children. Additionally, angioedema, atrioventricular (AV) block, and hypersensitivity can happen when alpha-2 agonists are prescribed. Beta-1 agonists have the potential to cause tremors, headaches, and vomiting. The following medical conditions make alpha-1 receptor agonists relatively contraindicated: hypertension, bradycardia, prostatic hyperplasia, and anyone using drugs that can raise blood pressure. Anyone with low blood pressure should utilize alpha-2 receptor agonists with caution. Because of the sedative and hypotensive effects, elderly people may be more likely to fall. Patients with arrhythmias should be cautious when using beta-1 receptor agonists. Patients with hypokalemia are generally contraindicated for beta-2 receptor agonists. Some anesthetics are comparatively contraindicated when used with norepinephrine. Hazardous arrhythmias are more likely to occur when halothane or cyclopropane dosages are used. It is not recommended for patients with angle-closure glaucoma to take epinephrine [7-12].

Observing. Each beta-2 agonist has a unique therapeutic index, and the therapeutic and side effects of comparable dosages can vary from person to person depending on a number of variables, including the severity of the ailment, the duration of the drug's use, and the patient's other medications. The degree of toxicity is correlated with the B2 agonists' plasma levels. Since the effectiveness and toxicity of B2 agonists can be assessed clinically or by indirect testing, direct monitoring is not a standard practice in clinical practice. However, there are some established methods for determining the amount of a drug in the blood, including high-performance liquid chromatography, fluorimetric detectors, electrochemical detectors, gas chromatography or liquid chromatography with mass spectrometry, and others. The main purpose of monitoring approaches is to check for their use as anabolic agents prior to athletic competitions. [5-11]. Clinically, blood glucose and serum potassium levels need to be regularly checked in order to address any negative consequences as soon as they occur. Since steroids are the primary medication

responsible for long-term effects, the recurrence of asthma attacks is not a reliable predictor of the effectiveness of B2 agonists [15,16].

Discussion. Adrenergic receptor function in AD has become a vital yet intricate research topic. The results of this review demonstrate the dual function of adrenergic receptors, highlighting both their potential for treatment and their roles in the pathophysiology of disease. This sophisticated knowledge highlights the difficulties in addressing such a complex system while also laying the foundation for creative therapeutic approaches. Numerous neurological functions, such as inflammation, neurovascular control, and synaptic plasticity, depend on α1, α2, and β1 and β2 subtypes of adrenergic receptors. Key AD diseases like Aβ buildup, tau hyperphosphorylation, and chronic neuroinflammation are now understood to be caused by dysregulation of adrenergic transmission, which is frequently brought on by early degeneration of the locus coeruleus. Although there are several treatment guidelines for common chronic diseases like asthma and COPD worldwide, beta-2 agonists are a crucial component of each one, which calls for in-depth and precise understanding of all relevant factors, including the serious side effects and contraindications [1-5]. Customizing a treatment plan based on all of the aforementioned elements is essential since practitioners should always respect the specific differences in each patient's response to treatment. Since beta-2 agonists can cause quick tolerance if taken improperly, patients need to be educated about when and how to use them. Beta-2 agonists are not the first-line medication for managing asthma. An interprofessional team of medical professionals, including pulmonologists or allergists, family clinicians (MDs, DOs, PAs, NPs), pharmacists, and nurses, should treat patients with chronic respiratory inflammatory diseases. These professionals should all be knowledgeable about the therapeutic use of beta-2 receptors and the medications that have agonistic or inhibitory effects on them. This information will be useful when choosing a therapy and while keeping an eye out for negative outcomes. All doctors, specialists, nurses, and pharmacists must work together and communicate openly in order to accomplish this. Each discipline must be given the authority to make recommendations and notify other team members of any changes in the situation. This will reduce the possibility of beta-2 receptor medication side effects while improving patient results. To improve efficacy and avoid side effects, cardiologists and obstetricians should determine the clinical significance of medications that influence B2 receptors that their patients may be taking and modify their prescriptions accordingly. Emergency physicians and nurses should be trained to correctly identify the clinical picture of an overdose of B2 agonists, and the general public needs more information about the dangerous consequences of using these drugs improperly or without medical advice, such as using them as anabolic drugs [8-12]. The review's conclusions confirm that adrenergic signaling plays a crucial part in the pathogenesis of AD and kindred tauopathies. Since they can alter a wide range of processes, including neuroinflammation, synaptic plasticity, and amyloid clearance, adrenergic receptors present a potential but difficult target for therapeutic development. Future studies should concentrate on creating medications that target certain receptor subtypes, investigating combination treatments that incorporate adrenergic regulation with additional neuroprotective

techniques, and customizing interventions for each patient's unique profile. Adrenergic receptor modification may open the door to revolutionary treatments for neurodegenerative illnesses by tackling these issues [13-19].

Conclusion. Adrenergic drugs come in a variety of forms, and clinicians who prescribe them—including doctors, nurse practitioners, and physician assistants—should be knowledgeable of their adverse effects and contraindications. Because these medications cover such a wide range of reasons and effects, both beneficial and negative, management calls for an interprofessional team approach to drug therapy. Any questions regarding the use of an adrenergic agent, including drug-drug interactions, the proper dosage depending on the condition being treated, and the adverse event profile, must be directed to a pharmacist. Because they frequently give the medications to patients while they are in the hospital, nurses can also use this resource to learn what symptoms to look out for in case of any kind of bad response. In order to make therapeutic adjustments, all interprofessional team members are required to report any changes in the patient's condition to the other team members and record them in the patient's medical file. To safely and successfully coordinate the treatment of patients receiving these drugs, an interprofessional team approach is essential.

The review highlights the complex function of adrenergic receptors in AD, emphasizing both their potential for treatment and their role in the pathophysiology of the disease. Neurovascular control, inflammation, and synaptic plasticity are among the neurological processes that physiologically depend on adrenergic receptors. Some preclinical studies highlight the detrimental effects of these receptors, despite encouraging preclinical research that suggests they could be effective therapeutic targets. Furthermore, there is a dearth of solid clinical evidence, and the few clinical studies that have been conducted so far have produced conflicting findings about the advantages of medications that operate on the β1 or β2 receptors.

The development of selective modulators is significantly hampered by the dual nature of receptor function, where both activation and inhibition may have comparable effects. Research in this field and treatment strategies are further complicated by genetic factors, patient-specific characteristics, the disease's intricacy, and the dearth of reliable animal models. In addition to using big data and sophisticated analytical approaches to improve tactics for adrenergic modulation in AD, future research should place a higher priority on the development of subtype-specific medications, combination therapy, and better controlled clinical trials with suitable covariate selection. Potentially, this could result in novel therapies for AD as well as other neurodegenerative illnesses.

References:

1. Farzam K, Kidron A, Lakhkar AD. Adrenergic Drugs. [Updated 2023 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534230/
2. Olson C, Jhawar A, Elfessi Z, Doyle R. Hydroxyzine-induced priapism. Am J Emerg Med. 2021 Oct;48:375.e5-375.e6.

3. Cooper J, Yang D. Case Report: Treatment of Myasthenic Ptosis with Topical Ocular Oxymetazoline. Optom Vis Sci. 2021 Nov 01;98(11):1317-1320.
4. Tasbihgou SR, Barends CRM, Absalom AR. The role of dexmedetomidine in neurosurgery. Best Pract Res Clin Anaesthesiol. 2021 Jul;35(2):221-229.
5. Keam SJ. Mirabegron: Pediatric First Approval. Paediatr Drugs. 2021 Jul;23(4):411-415.
6. Porto R, Mengarda AC, Cajas RA, Salvadori MC, Teixeira FS, Arcanjo DDR, Siyadatpanah A, Pereira ML, Wilairatana P, Moraes J. Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni. Pharmaceuticals (Basel). 2021 Jul 16;14(7)
7. Ashkar H, Adnan G, Patel P, Makaryus AN. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 23, 2024.
8. Dobutamine. Cox C, Patel K, Cantu R, Akmyradov C, Irby K. Hypokalemia Measurement and Management in Patients With Status Asthmaticus on Continuous Albuterol. Hosp Pediatr. 2022 Feb 01;12(2):198-204.
9. Mitchell BG, Lee J. Case Report: Concurrent Clonidine Abuse and Opioid Use Disorder. J Psychoactive Drugs. 2021 Sep-Oct;53(4):373-377.
10. Johnson DB, Merrell BJ, Bounds CG. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 10, 2024. Albuterol.
11. Abosamak NER, Shahin MH. Beta2 Receptor Agonists and Antagonists. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559069/
12. Burkes RM, Panos RJ. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. J Exp Pharmacol. 2020;12:589-602.
13. Kintz P, Gheddar L, Ameline A, Dumestre-Toulet V, Verschoore M, Comte J, Raul JS. Complete Post-mortem Investigations in a Death Involving Clenbuterol After Long-term Abuse. J Anal Toxicol. 2019 Sep 10;43(8):660-665.
14. Crossingham I, Turner S, Ramakrishnan S, Fries A, Gowell M, Yasmin F, Richardson R, Webb P, O'Boyle E, Hinks TS. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021 May 04;5(5):CD013518.
15. Colombo M, Plebani A, Bosco A, Agosti M. Severe lactic acidosis and persistent diastolic hypotension following standard dose of intermittent nebulized salbutamol in a child: a case report. J Med Case Rep. 2022 Apr 22;16(1):160.
16. Koraćević G, Stojanović M, Kostić T, Lović D, Zdravković M, Koraćević M, Pavlović D, Mićić S. Contraindications Differ Widely Among Beta Blockers and Ought to be Cited for an Individual Drug, Not for the Entire Class. Curr Pharm Des. 2021;27(40):4125-4132.
17. Miliotou AN, Kotsoni A, Zacharia LC. Deciphering the Role of Adrenergic Receptors in Alzheimer's Disease: Paving the Way for Innovative Therapies. Biomolecules. 2025; 15(1):128. https://doi.org/10.3390/biom15010128
18. Hohberger, B.; Prüss, H.; Mardin, C.; Lämmer, R.; Müller, J.; Wallukat, G. Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance. PLoS ONE 2022, 17, e0272811.

19. Kikuchi, K.; Fujita, Y.; Shen, X.; Liu, J.; Terakawa, T.; Nishikata, D.; Niibori, S.; Ito, T.; Ashidate, K.; Kikuchi, T.; et al. Interaction between Angiotensin Receptor and beta-Adrenergic Receptor Regulates the Production of Amyloid beta-Protein. Biol. Pharm. Bull. 2020, 43, 731–735.